The Relation Between Serum Zinc and Lupus Nephritis

Not yet recruiting

• Conditions: Lupus Nephritis

• Registration Number: NCT06564181
• Lead Sponsor: Assiut University

Brief Summary

The goal of this observational study is to investigate the relation between serum zinc and lupus nephritis by search Prevalence of hypozincemia in lupus nephritis and Association between serum zinc and urea, serum creatinine, hemoglobin, eGFR .

Detailed Description

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting various organs including the skin, joints, kidneys, brain and heart...

Lupus nephritis (LN) is one of the most common severe organ manifestations of SLE . LN is clinically evident in 50-60% of patients with SLE , and it is histologically evident in most SLE patients, even those without clinical manifestations of kidney disease.

LN is associated with significant morbidity and mortality in SLE patients, as up to 20% of patients progress to end-stage renal disease (ESRD). The clinical manifestations of LN are variable, ranging from asymptomatic proteinuria to a myriad of manifestations associated with nephritic and nephrotic syndromes and ESRD.

Zinc is a vital micronutrient involved in numerous physiological processes including immune function, antioxidant defense, and cellular repair. It is a cofactor for over 300 enzymes and plays critical roles in DNA synthesis, protein production, and cell division. Zinc deficiency can impair immune function, increase oxidative stress, and hinder tissue repair, which are all relevant factors in autoimmune diseases like SLE, making its study in the context of LN particularly relevant.

However, further research is needed to fully understand the mechanisms and to develop evidence-based guidelines for zinc supplementation in lupus nephritis patients.

Study Timeline

• Status Verified: 2024-08
• Study First Submitted: 2024-08-19
• Study First Submitted QC: 2024-08-19
• Last Update Submitted: 2024-08-20
• Study First Posted: 2024-08-21
• Last Update Posted: 2024-08-22
• Study Start: 2024-09-01
• Primary Completion: 2025-09
• Study Completion: 2025-10

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Patients with lupus nephritis (diagnosed SLE and LN according to EULAR criteria 2019)

Exclusion Criteria

1. other patients with other renal diseases .
2. patients with other autoimmune diseases.
3. patients on dialysis.
4. patients with Diabetes mellitus.

6- patients with liver diseases.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of hypozincemia in lupus nephritis Correlation between hypozincemia and urea , S. Creatinine and eGFR	1/9/2024 - 1/9/2025	Prevalence of hypozincemia in lupus nephritis